Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 15,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $243.72, for a total transaction of $3,655,800.00. Following the completion of the transaction, the director now owns 449,201 shares in the company, valued at approximately $109,479,267.72. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Shares of Illumina, Inc. (ILMN) traded up $3.84 during trading on Monday, hitting $221.03. The stock had a trading volume of 1,000,000 shares, compared to its average volume of 1,100,000. Illumina, Inc. has a 1-year low of $158.02 and a 1-year high of $248.97. The firm has a market capitalization of $32,270.00, a P/E ratio of 44.83, a PEG ratio of 2.87 and a beta of 0.92. The company has a debt-to-equity ratio of 0.42, a quick ratio of 3.55 and a current ratio of 3.99.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, January 30th. The life sciences company reported $1.44 EPS for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.22. Illumina had a return on equity of 21.52% and a net margin of 26.56%. The business had revenue of $778.00 million during the quarter, compared to the consensus estimate of $752.04 million. During the same period in the previous year, the company posted $0.85 earnings per share. The business’s revenue for the quarter was up 25.7% on a year-over-year basis. analysts forecast that Illumina, Inc. will post 4.59 EPS for the current year.
ILMN has been the topic of a number of research analyst reports. Wells Fargo & Co raised shares of Illumina from a “market perform” rating to an “outperform” rating and set a $205.00 price target on the stock in a research note on Tuesday, January 2nd. Morgan Stanley lifted their price target on shares of Illumina from $122.00 to $135.00 and gave the company an “underweight” rating in a research note on Thursday, December 14th. Citigroup raised their price objective on Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a report on Wednesday, October 25th. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $252.00 price objective on the stock in a report on Tuesday, December 5th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $269.00 price objective on shares of Illumina in a report on Tuesday, January 9th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $241.39.
Several institutional investors have recently made changes to their positions in ILMN. Intellectus Partners LLC lifted its stake in Illumina by 6.6% during the second quarter. Intellectus Partners LLC now owns 10,783 shares of the life sciences company’s stock worth $1,871,000 after purchasing an additional 664 shares during the last quarter. Axiom International Investors LLC DE lifted its stake in Illumina by 60.9% during the third quarter. Axiom International Investors LLC DE now owns 186,457 shares of the life sciences company’s stock worth $37,142,000 after purchasing an additional 70,572 shares during the last quarter. Virtu Financial LLC purchased a new stake in Illumina during the third quarter worth approximately $577,000. Creative Planning lifted its stake in Illumina by 9.8% during the fourth quarter. Creative Planning now owns 12,384 shares of the life sciences company’s stock worth $2,706,000 after purchasing an additional 1,107 shares during the last quarter. Finally, Gateway Investment Advisers LLC lifted its stake in Illumina by 3.5% during the fourth quarter. Gateway Investment Advisers LLC now owns 95,711 shares of the life sciences company’s stock worth $20,912,000 after purchasing an additional 3,202 shares during the last quarter. 92.04% of the stock is owned by institutional investors and hedge funds.
WARNING: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/12/insider-selling-illumina-inc-ilmn-director-sells-3655800-00-in-stock.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.